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ABSTRACT
We analyzed the in vitro eﬀ ects of the anti-tumoral drugs doxorubicin, cytosine arabinoside and hydroxyurea on the G2-prophase 
checkpoint in lymphocytes from healthy individuals. At biologically equivalent concentrations, the induced DNA damage activated the 
corresponding checkpoint. Thus: i) there was a concentration-dependent delay of G2 time and an increase of both the total DNA lesions 
produced and repaired before metaphase and; ii) G2-checkpoint adaptation took place as chromosome aberrations (CAs) started to appear 
in the metaphase, indicating the presence of unrepaired double-strand breaks (DSBs) in the previous G2. The checkpoint ATM/ATR kinases 
are involved in DSB repair, since the recorded frequency of CAs increased when both kinases were caﬀ eine-abrogated. In genotoxic-treated 
cells about three-fold higher repair activity was observed in relation to the endogenous background level of DNA lesions. The maximum 
rate of DNA repaired was 3.4 CAs/100 metaphases/hour, this rise being accompanied by a modest 1.3 fold lengthening of late G2 prophase 
timing. Because of mitotic chromosome condensation, no DSBs repair can take place until the G1 phase of the next cell cycle, when it occurs 
by DNA non-homologous end joining (NHEJ). Chromosomal rearrangements formed as a consequence of these error-prone DSB repairs 
ensure the development of genome instability through the DNA-fusion-bridge cycle. Hence, adaptation of the G2 checkpoint supports the 
appearance of secondary neoplasia in patients pretreated with genotoxic drugs.
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INTRODUCTION
In proliferating cells, checkpoints are protein-to-protein 
pathways that sense a risky condition for a cell facing its 
irreversible transition to the following cycle phase. They 
then transduce antimitogenic signals to transiently delay 
such phase transition until it becomes safe for the cell. Most 
checkpoints are activated by DNA structural changes, such 
as those produced by deficiencies in DNA decatenation, 
replication or repair, although they also respond to other 
conditions, such as faulty achievement of a certain cell mass 
threshold for mitosis to be initiated. The checkpoint pathways 
activated by DNA damage are formed by early (proximal) 
kinases, which senses and initiates signaling, intermediate 
transducers of antimitogenic signals, and downstream eﬀ ector 
kinases, such as CHK1, CHK2 and MAPKAPK2 (Zhang et al., 
2008)
Checkpoints, when activated by DNA lesions, initiate 
two sub-pathways. The fi rst stimulates the transcription of 
genes coding for enzymes responsible for DNA repair (Zhou 
and Elledge, 2000). The second subpathway blocks CDK 
machinery, usually by inhibiting Cdc25 phosphatase and 
then preventing the mitogenic dephosphorylation of the T14/
Y15 residues in the CDK catalytic subunit (Sanchez et al., 
1997). As a consequence of the latter checkpoint subpathway, 
the proliferating cell has more time to complete the missing 
requirement that activated the checkpoint, increasing the total 
amount of DNA repair that takes place before the irreversible 
transition to the following cycle phase.
Finally, when DNA damage overrides the repair ability 
of a particular cell, the checkpoint pathway acquires a 
third function. It then induces apoptosis by activating the 
corresponding program (Bernstein et al., 2002). This latter 
function is the only one that supports a tumor suppressor 
function of checkpoint activation.
Though the checkpoint stringency diﬀ ers in the diﬀ erent 
cycle phase transitions they control, any checkpoint-induced 
block is always transient. Thus, such a block is spontaneously 
overridden after some time, even though the requirement 
that activated the checkpoint remains partially unfulfilled 
(Paulovich et al., 1997). This property is known as checkpoint 
adaptation.
Adaptation to the G2 checkpoint is unique as the DNA 
lesions that are not repaired in G2-prophase will be processed 
to chromosomal aberrations (CAs) (Lee et al., 1997). Thus, 
both premitotic chromatid individualization and mitotic 
chromosome condensation result in the DNA lesions present 
in late G2 remaining unrepaired until the G1 of the subsequent 
cell cycle. In G1, the absence of the sister chromatid with an 
undamaged copy of lost or damaged DNA sequences results in 
DSB repair taking place by a non-homologous recombination 
mechanism. As a consequence, chromosomal rearrangements 
are induced, which initiate the DNA breakage-fusion-bridge 
cycle that supports the development of genomic instability to 
be clonally inherited by the progeny of each cell adapted to the 
G2 -prophase checkpoint (McClintock, 1984).
In the present report,  we study the response of 
lymphocytes from healthy individuals in vitro exposed 
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to four moderate doses of three different genotoxic drug 
treatments performed specifi cally during the G2-prophase. 
The treatments comprise the anthracycline antibiotic drug 
doxorubicin/adriamycin (DOX), the antimetabolite cytosine 
arabinoside, also known as arabinosyl-cytosine and cytarabine 
(ara C), which incorporates into DNA, and fi nally hydroxyurea 
(HU), which prevents the formation of deoxyribonucleotides 
by inhibiting the ribonucleotide reductase enzyme. These 
three antitumoral drugs behave as eﬃ  cient genotoxic and 
clastogenic agents that modify DNA structure and function in 
the cells that are replicating their DNA. Nevertheless, each of 
these drugs displays other drug-specifi c eﬀ ects. Hence, DOX 
generates reactive oxygen species (Gajewski et al., 2007), and 
prevents the binding of topoisomerase II to DNA because of its 
intercalation among adjacent DNA bases. On the other hand, 
ara C when incorporated into DNA, prevents elongation of 
the freshly initiated DNA chains, and also inhibits excision 
repair by blocking the action of α, δ and ε DNA polymerases 
(Mirzayans et al., 1993), whereas HU inhibits both nuclear 
DNA replication and repair (Müller et al., 2005).
Our results showed that in proliferating lymphocytes 
from healthy donors, the three antitumoral drugs assayed are 
also genotoxic when applied to late G2-prophase when cells 
perform their post-replication DNA repair. The frequency of 
chromosomal aberrations recorded in the metaphase increased 
with treatment concentration in the previous G2-prophase. 
The induced block that the checkpoint induces in G2-prophase 
progression was consistently overridden before DNA repair 
was complete (checkpoint adaptation). These data altogether 
support that genotoxic drugs, because of their eﬀ ect on post-
replication DNA repair, activate the G2-prophase checkpoint, 
which in turn promotes the development of genomic instability 
instead of preventing it.
MATERIALS AND METHODS
The study included 30 control individuals in good health, from 20 
to 40 years of age (15 males and 15 females). These controls were 
assigned into three groups of ten individuals; each group was 
used to evaluate the in vitro eﬀ ects of DOX, araC or HU separately. 
To each drug assay, the blood samples (10 mL) from each of the 
ten individuals was used to set up 25 whole blood lymphocyte 
cultures. Ten of them were used to evaluate chromosomal 
aberrations and the remaining 15 to estimate G2 timing.
For each culture, 0.4 mL of blood was added to 5 mL of 
TC medium RPMI 1640 (Gibco), supplemented with 20% 
heat-inactivated fetal bovine serum (Gibco), 1% penicillin and 
streptomycin and 2% phytohemagglutinin (M Form, Gibco). 
Cultures were incubated at 37ºC for 72 h. Then, the cells were 
blocked in metaphase by adding 0.2 μg/mL colcemid (Karyo 
Max, Gibco) during the last 3 h before harvesting.
Drug solutions and treatments
The three antitumoral drugs assayed (DOX, ara C and HU) 
were all from Sigma. Their CAS registry numbers were 69-74-
9, 127-07-1 and D1515, respectively. These drugs, as well as 
caﬀ eine (Merck, CAS 58-08-2), the inhibitor of the checkpoint 
ATM and ATR kinases (Sarkaria et al., 1999), were diluted 
in TC medium RPMI 1640 to obtain the corresponding stock 
solutions. They were diluted again to get the concentrations 
specifi ed for each treatment in the Results section.
Evaluation of chromosomal aberrations
Two of the 10 cultures set up were used to determine the 
frequency of CAs under control conditions. These CAs 
represent the basal metabolic DNA damage without any 
genotoxic treatment. They are displayed in the fi rst row of 
Table 1, either when the ATM and ATR kinases activities were 
suppressed by caﬀ eine (column B in Table 1) or when they 
remained functional, i.e. in the absence of added caﬀ eine 
(column A in the same Table).
The other 8 cultures were divided into 4 pairs and each 
treated with one of the four drug concentrations assayed. 
Again, one of each pair of cultures was used to determine 
the yield of chromosome aberrations induced by the drugs 
(column A), while the other was additionally treated with 
5mM caﬀ eine in order to inhibit the activity of the checkpoint 
kinases ATM/ATR during G2-prophase, i.e. in the last 3 h 
before metaphase harvesting (column B).
For chromosomal analysis,  air-dried preparations 
were Giemsa-stained according to standard procedures. A 
minimum of 50 metaphase plates from coded slides for each 
culture were scored for chromosomal aberrations by two 
independent people. The chromosomal aberrations (CAs) 
included chromatid breaks, chromosome/isochromatid breaks, 
chromatid exchanges, dicentrics and ring chromosomes. 
Chromatid or isochromatid breaks were diagnosed when 
the distal chromatid segments were dislocated from the 
chromosomal axis or when the unstained segment was larger 
than the chromatid width.
Metaphases with more than 12 CAs and/or fragmented 
chromosomes were excluded from the basic aberration scores. 
This exclusion was performed because of the diﬃ  culties in 
estimating the CAs score and because they probably do not 
remain in this proliferative compartment but rather activate the 
apoptosis program. Interchromatid bridges were also excluded 
from the aberration score. They correspond to unresolved 
chromatid bridges, which formed selectively in response to 
DOX, due to its eﬀ ect as a DNA intercalating drug.
Evaluation of G2 timing
G2 length was determined by the labelled metaphase technique 
(Mitchell et al., 1979), always in the absence of caﬀ eine, so that 
ATM/ATR activity was undisturbed. The three control cultures 
(without genotoxic) and the 12 cultures corresponding to the 
four assayed drug concentrations were treated with a fi nal 
1 μCi/mL [3H] TdR concentration of 25 Ci/mmol specifi c 
activity (Amersham Radiochemical Center, UK) for 4, 5 and 6 h 
before harvesting. In the last 3 h of incubation, the 12 cultures 
treated with the genotoxic drugs at the diﬀ erent concentrations 
specified so that 3 cultures were obtained per each drug 
concentration. Metaphases were later accumulated by adding 
0.2 μg/mL colcemid.
For autoradiography, air-dried preparations were dipped 
in EM-1 hypercoat emulsion RPN-41 (Amersham Biosciences, 
Uppsala, Sweden), placed in the dark at 4ºC, and after seven 
days of exposure, they were developed and then stained with 
4% Giemsa. Scoring of at least 300 labelled metaphases was 
carried out in coded slides by two independent people. Mean 
G2 timing was estimated by taking into account the [3H] TdR 
incubation time at which 50% of the metaphases were [3H]-
labelled for each experimental condition.
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For each drug, the relationship between both chromosomal 
aberrations and G2 timing was assessed in function of the 
treatment concentration. The statistical signifi cance of the mean 
values was estimated from the correlation coeﬃ  cients (r) and 
the Student´s t test. Minimum signifi cance was considered 
to occur at a maximum P value of 0.05. Only un-signifi cant 
P-values for correlation coeﬃ  cients are denoted.
RESULTS
Endogenous (basal) DNA damage in the G2-prophase of control 
lymphocytes
The experimental protocol used in the present work restricts 
the exposure of human lymphocytes to antitumoral drugs 
to the last three hours before metaphase. As the mean 
length of the G2 phase in lymphocytes from control donors 
corresponded to 4.4 ± 0.2 hours, confi rming previous results 
(Pincheira et al., 1993), the 3-hour treatment occupies an 
important part of G2, excluding only early G2.
In the absence of any genotoxic drug, lymphocytes 
displayed a few chromosomal aberrations both when caﬀ eine 
was applied to cancel the checkpoint kinases ATM/ATR (6.3 
± 1.0 CAs per 100 metaphases; column B in Table 1) and also 
when these kinases remained functional, i.e. in the absence 
of caﬀ eine (1.1 ± 0.5 CAs per 100 metaphases, column A in 
Table 1). The diﬀ erence between the two values (6.3 minus 
1.1 CAs/100 metaphases) corresponds to the DNA lesions 
repaired before their processing into CAs. Accordingly, when 
no functional ATM/ATR kinases were present, the reduction of 
5.2 CAs per 100 metaphases (column C in Table 1) was due to 
the inhibition of DNA repair.
Eﬃ  ciency of the genotoxic drugs on the induction of chromosomal 
aberrations
To select biological equivalent drug concentrations, we 
previously evaluated (data not shown) the concentration at 
which each drug treatment induced DNA damage (recorded 
as CAs) in slightly over 50% per 100 metaphases when the 
ATM/ATR kinases were cancelled by 5 mM caﬀ eine. In this 
way, both increases and decreases in DNA damage could be 
easily followed. Concentrations at which the presence of CAs 
per 100 metaphases was slightly over those corresponding to 
endogenous DNA damage (6.3 ± 1.0 in fi rst row, column B) 
were the lowest ones to be studied.
TABLE 1
DNA lesions in human lymphocytes under basal conditions and at different concentrations of DOX, ara C or HU, recorded as chromosomal 
aberrations (CAs) per 100 metaphases. (A) Unrepaired DNA lesions both in the presence of ATM/ATR checkpoint kinases and (B) after 
their caffeine-induced abrogation (Sarkaria et al. 1999). (C) DNA lesions repaired in the presence of the ATM/ATR kinases (no caffeine) (D) 
Estimated G2-prophase timings in hours and (E) rates of DNA repair in CAs per 100 metaphases per hour.
DNA lesions
Repaired DNA lesions
(+ ATM/ATR)
G2-prophase
Rate of DNA 
repair
Treatments (+ ATM/ATR)
A
(- ATM/ATR)
B
C = B –A
time (+ ATM/ATR)
D
E = C /D
None (*) 1.1 ± 0.5 6.3 ± 1 5.2 4.4 ± 0.1 1.2
DOX [μΜ]
0.002 3.8 ± 1 11.5 ± 2 7.7 4.5 ± 0.1 1.7
0.02 9.6 ± 3 17.3 ± 3 7.7 4.6 ± 0.2 1.7
0.2 19.2 ± 3 29.0 ± 3 9.6 5.1 ± 0.2 1.9
2.0 38.9 ± 4 57.0 ± 6 18.1 5.7 ± 0.3 3.2
ara C [μΜ]
0.01 2.1 ± 1  7.7 ± 2 5.6 4.8 ± 0.2 1.2
0.1 6.8 ± 2 16.6 ± 4 9.8 5.1 ± 0.2 1.9
1.0 15.3 ± 3 28.7 ± 5 13.4 5.4 ± 0.2 2.5
10.0 37.9 ± 6 55.0 ± 4 17.1 5.9 ± 0.3 2.9
HU [mM]
1.0 5.6 ± 1 12.2 ± 2 6.6 4.9 ± 0.2 1.3
2.5 13.4 ± 3 22.3 ± 2 8.9 5.1 ± 0.2 1.7
5.0 20.3 ± 2 35.6 ± 5 15.3 5.5 ± 0.2 2.8
10.0 31.9 ± 6 51.2 ± 5 19.3 5.7 ± 0.3 3.4
Highest to endogenous ratio in the column – – 3.7 1.3 2.8
The mean values ± S.E. in the fi rst row correspond to genotoxic-untreated lymphocytes from 30 healthy blood donors and represent the endogenous (basal) DNA 
damage produced mostly by oxidative metabolism. In contrast, the responses to each drug correspond to the mean values ± SE estimated in 10 healthy individuals. 
Bold fi gures in C, D and E represent the highest value recorded in each particular column.
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Obviously our choice did not ensure the strict equivalence 
of the concentrations of the diﬀ erent drug treatments, although 
the approach appeared as an acceptable estimate for their 
comparison.
First  of  al l ,  the data showed that  the range of 
concentrations at which the amount of CAs DOX and ara C 
induced changed from the minimum to the maximum selected 
concentration as much as 1,000 times, the corresponding 
maximum being 2.0 μM and 10 μM for DOX and ara C, 
respectively. At the same concentrations, the minimum values 
for the induced CAs were 0.002 μM for DOX and 0.01 μM for 
ara C.
On the other hand, the range of active concentrations for 
HU was narrower than those for DOX or ara C. Thus, the 
selected minimum and maximum concentrations changed by 
a single order of magnitude (1 mM and 10 mM, respectively).
Effect of the genotoxic drugs applied during G2-prophase in CAs 
frequency
The residual presence of CAs supports that the activation 
of the G2-prophase checkpoint was followed by checkpoint 
adaptation, a process that is also taking place under 
endogenous metabolic stress. Hence, the control cells when 
untreated with any genotoxic agent also overrode the 
checkpoint-induced G2-prophase block precociously, i.e. 
before the repair of DNA damage recorded as DSBs was over. 
In control cells, most of the DNA damage present was that 
induced by oxidative metabolism and, probably, by some stress 
induced by the in vitro cell culture. The CAs induced under 
these basal conditions remained constant while the growth 
conditions stayed unmodifi ed.
When no caffeine was added, the frequency of CAs 
was reduced (column A in Table 1) in comparison to values 
obtained when the simultaneous ATM/ATR kinases activity 
was cancelled by caﬀ eine (column B). However, the frequency 
of CAs increased in a drug concentration-dependent manner 
in both experimental conditions. The corresponding correlation 
coeﬃ  cients (r) for the regression lines recorded were 0.927 
and 0.941 for DOX; 0.959 and 0.931 for ara C, and 0.985 and 
0.988 for HU, both in the presence and the absence of caﬀ eine 
(columns A and B), respectively.
It was also estimated how much of the recorded 
chromosomal damage was produced in response to the 
antitumoral drugs and how much was produced by 
metabolism. Then the frequency of endogenous DNA damage 
recorded as CAs in the absence of caffeine (1.1 CAs/100 
metaphases) was subtracted from the total frequency of CAs 
recorded at diﬀ erent drug concentrations (column A, Table 1). 
Equivalent estimations were carried out when caﬀ eine was 
added (column B in Table 1).
The diﬀ erences between frequency of CAs recorded in the 
presence (column B, Table 1) and in the absence of caﬀ eine 
(column A) represent the amount of DNA lesions repaired 
through the activation of the G2-prophase checkpoint, i.e. 
in the presence of functional ATM/ATR kinases (no caﬀ eine 
added). The estimated DNA lesions repaired are displayed 
in column C of Table 1. In the range of drug concentrations 
assayed, the amount of DNA being repaired increased linearly 
with drug concentration and then with the DNA damage 
induced by each specific treatment. The corresponding 
correlation coeﬃ  cients for the recorded values were 0.966, 
0.825 and 0.975 for DOX, ara C and HU, respectively.
It was obvious that lymphocytes were able to repair nearly 
4 times more DNA lesions in response to 10 mM HU (last 
row, column C in Table 1) than when no genotoxic drug was 
applied (fi rst row, in the same column). In this last situation, 
the only DNA damage present was that induced by oxidative 
metabolism and probably by some stress arising from the 
specific cell culture conditions. The CAs induced under 
these basal conditions remained constant while the growth 
conditions remained the same.
As recorded in column C of Table 1, at the lowest drug 
concentrations, the level of CAs per 100 metaphases was 
similar in the ara C-treated cells to that in the control cells 
exposed only to the basal DNA damage. This basal value 
was increased in 1.4 under HU (6.6) and in 2.5 under DOX 
(7.7). Thus, at the lowest drug concentration most of the 
DNA lesions detected as CAs are formed in response to cell 
metabolism, while the remaining ones represent the processing 
products of the genotoxic eﬀ ect that each drug treatment had 
during G2 -prophase.
Does the drug-induced DNA damage activate the G2-prophase 
checkpoint?
Three facts support the drug-induced activation of the studied 
checkpoint. First of all, though the DNA damage induced by 
either metabolism or by the applied drugs is repaired in the 
absence of the checkpoint ATM/ATR kinases, the activation of 
these kinases increases the amount of the DSB repaired.
Secondly,  G2-prophase timings were recorded in 
proliferating lymphocytes from healthy individuals, both 
under control conditions and after the diﬀ erent treatments 
with the three anti-tumoral drugs. The data obtained (column 
D in Table 1) proved that the G2-prophase checkpoint pathway 
was activated by these drugs. Thus, the G2-prophase timings 
increased in a drug concentration-dependent manner in 
relation to the mean value recorded in the control lymphocytes 
untreated with any antitumoral drug. The correlation 
coeﬃ  cients for the corresponding regression lines were 0.910, 
0.808 and 0.909 for DOX, ara C and HU, respectively.
Lastly, the presence of CAs in metaphase after the 
treatment protocol here applied shows that checkpoint 
adaptation has taken place immediately after cell exposure to 
the genotoxic drugs during previous G2 and prophase. Only 
checkpoint adaptation is compatible with the entry into mitosis 
of the cells with still unrepaired DNA damage as CAs.
How much DNA damage induced in G2-prophase reaches metaphase still 
unrepaired?
Only a portion of the DNA damage produced in this part of the 
cycle by the oxidative metabolism or by the genotoxic drugs 
were repaired during G2-prophase. In fact, the unrepaired 
DNA constituted the most important portion of the total DNA 
lesions induced by the antitumoral treatments, as it occurred 
at the highest drug concentrations, where the amount of 
intranuclear DNA damage reached its maximum.
Thus, the amount of DNA damage increased from the 
residual 1.1 CAs per 100 metaphase recorded for the metabolic 
DNA damage produced in control conditions up to the 
maximum 38.9 CAs per 100 metaphases recorded in response 
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to 2 μM DOX treatment (column A in Table 1). The frequency 
of the DNA lesions remaining unrepaired because G2-prophase 
checkpoint adaptation increased with concentration in 
response to any of the three assayed genotoxic drugs (column 
A).
How is the eﬃ  ciency of DNA repair modulated in lymphocytes?
The eﬃ  ciency of DNA repair was estimated in the presence of 
each antitumoral drug treatment assayed during G2-prophase 
by taking into account the total DNA lesions repaired (column 
C, Table 1) and the mean G2 time that these cells need to repair 
them (column D in Table 1). The estimated values for the rate 
of DNA repair are shown in last column of Table 1 (column E). 
There is a linear increase in the rate of DNA repair in response 
to increased DNA damage, the correlation coeﬃ  cients for the 
regression lines obtained were 0.956 for DOX and 0.969 for HU 
(P <0.05), while r was 0.761 for ara C (T=2.1; 0.1 >P> 0.05).
While the rate of repair for the endogenous damage 
produced by metabolism was of 1.2 CAs/100 metaphases 
per h, it increased to 1.7 CAs/100 metaphases per h for 
the two lowest DOX concentrations. It remained similar to 
the endogenous DNA damage for the minimum assayed 
concentrations of either ara C or HU.
On the other hand, the maximum levels reached by the 
rate of DNA repair took place at the highest assayed dose of 
each drug treatment. The maximum rates of DNA repair were 
3.2, 2.9, and 3.4 CAs/l00 metaphases per hour for DOX, ara 
C and HU, respectively (column E Table 1). Thus, the highest 
DNA repair rate was 2.8 fold higher than that displayed for the 
repair of the metabolism-induced DNA lesions. A modest 1.3 
fold lengthening of the G2-prophase timing helps to increase 
DNA repair at the maximum drug concentrations assayed.
DISCUSSION
The presence of CAs in mitosis does not result from saturation 
of the cell repair capability in the previous G2-prophase. 
Hence, lymphocytes repaired up to 3.7 times more DNA lesions 
in response to 10 mM HU than under control conditions (where 
only endogenous lesions due to oxidative metabolism were 
present).
Adaptation to the G2-prophase checkpoint seems to be 
responsible for the appearance of CAs in mitosis. The recorded 
checkpoint-induced G2-prophase lengthening produced 
in response to the genotoxic drugs took place during those 
specifi c cycle phases. Furthermore, CAs increased the G2-
prophase checkpoint when abrogated by caﬀ eine and when the 
cooperation of the checkpoint ATM/ATR kinases to repair the 
drug-induced DNA lesions was precluded (column B in Table 
1). Finally, only adaptation to the G2-prophase checkpoint 
makes cells enter into mitosis before DNA repair is completed. 
The participation of ATM/ATR in the DNA repair and G2-
checkpoint mechanisms is well known since Sarkaria et al., 
(1999) reported it.
Checkpoint adaptation acquires a new signifi cance when 
we think of it as a genetically programmed process for specifi c 
chromosomal situations. Thus, its evolutionary conservation 
favors experiments on microevolution in somatic cells where 
DNA has previously been damaged and this damage has 
activated the G2-prophase checkpoint. The trial and error 
assays on genome re-structuring that these experiments 
imply might improve the survival of the genetically modifi ed 
progeny of each checkpoint-adapted cell, no matter how low 
the probability for increasing cell proliferation capability 
might be.
In cell cultures of ataxia telangiectasia patients, the 
spontaneous release from the G2 checkpoint-induced block 
(checkpoint adaptation) takes place when the presence of 3 or 
4 chromosomal aberrations is ensured immediately following 
mitosis (Deckar et al., 2007). The threshold for spontaneous 
override of the G2-prophase checkpoint-induced cycle block 
increases with DNA damage, as shown here (by the present 
results). This is consistent with the fact that the threshold 
nearly trebled in the cells of patients with chromosome 21 
trisomy that displays increased oxidative DNA damage 
(Pincheira et al., 2007).
In terms of energy cost, the G2-prophase checkpoint 
appears not to be as efficient as the previous one, which 
controls the G1 to S transition to transiently stop cell 
proliferation when the conditions of a cell are not adequate to 
deal safely with the new ones which the cell would face after 
irreversible onset of replication. However, the G2-prophase 
checkpoint has some features that increase its strategic value 
when compared to the G1 to S checkpoint. Thus, nuclear DNA 
damage reaches the G2 -prophase period after adaptation to 
previous intra S checkpoints, so that the DNA lesions are far 
more abundant in late interphase than earlier in the cell cycle 
(Bernstein et al., 2002).
The G2-prophase checkpoint is even more crucial for cell 
survival in the already transformed cells than in the control 
ones. Thus, nearly half of all human tumors lack some of 
the active isoforms of the checkpoint protein p53, with the 
consequence that the previous checkpoint controlling the G1 
to S transition is constitutively inactive in them (Levine, 1997).
Genome instability: the unsuspected consequence of G2-prophase 
checkpoint operation
The response of normal lymphocytes to the three assayed 
antitumoral drugs allows us to conclude that activation of the 
G2-prophase checkpoint and the subsequent adaptation to the 
block that it induces in cell progression will be followed by the 
undue entry of cells with DNA breaks into metaphase.
As commented above, adaptation to the G2-prophase 
checkpoint but not to any other checkpoint challenges 
the cell in a unique way because there is a shift in the 
way that DSBs are repaired. This shift is produced both 
because of topoisomerase II-dependent premitotic chromatid 
individualization (Gimenez-Abian et al., 2000) and, also, 
because of chromosomal condensation, the main epigenetic 
process that represses gene expression in mitosis.
As a consequence, DSBs repair waits until G1 of the next 
cell cycle. Then, repair proceeds by an error-prone DNA 
recombination since these chromosomes are still unreplicated 
and the intact sequences in the homologous chromosomes 
are far apart and consequently not available to be copied for 
homologous recombination. Instead, the repair of DSBs in 
G1 has to proceed by non-homologous end-joining (NHEJ), 
as supported by the DNA-PKcs activity requirement for 
premature release of the G2 checkpoint (Lee et al., 1997).
The main drawback of the inaccurate joining of two 
unrelated free DNA ends located either in the same or 
diﬀ erent chromosomes is that it gives rise to chromosomal 
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rearrangements such as translocations, dicentrics and other 
types of unstable chromatid rearrangements. Resolution of 
the ectopic DNA bonds produced by NHEJ repair of the drug-
induced DSBs takes place during the immediately following 
anaphase-telophase. This is mediated by random chromosomal 
cuts formed as a consequence of sister centromeres stretching 
towards opposite spindle poles. This results in the appearance 
of new DSBs that are again ectopically repaired in the 
following cell cycle. They are clonally inherited throughout 
subsequent cell cycles by following the universal DNA 
breakage-fusion-bridge cycle (McClintock, 1984) that ensures 
the clonal transmission of genomic instability.
In relation to the induction of genome instability in 
leukemia-treated children (Finette et al., 2000), it is worth 
remembering that microsatellite instability is brought about 
when the mismatch repair system in the G2-prophase is 
disturbed (Hawn et al., 1995).
G2-prophase checkpoint adaptation and secondary neoplasias
The results presented here show that the activation of the 
G2-prophase checkpoint favors, instead of preventing, the 
appearance of secondary neoplasias in the non-transformed 
cells of cancer patients, in a late response to previous 
antineoplastic drugs that damaged the DNA. Then, it cannot be 
assumed that checkpoints are tumor-suppressing mechanisms. 
Only when DNA damage overrides the cell’s ability to repair 
itself does checkpoint-mediated induction of apoptosis take 
place and only then does the activation of the checkpoint result 
in a desirable antitumoral eﬀ ect since every apoptotic cell is 
excluded from the next generation. At the drug concentrations 
and incubation times considered in this work, no apoptotic 
body programs responsible for apoptosis (Bernstein, 2002) 
were detected at late incubation times. Of these, only 
metaphases displaying many CAs probably endure a mitotic 
catastrophe and are excluded from the next cell generation.
The present results that a major objective for the 
development of safe antitumoral treatments based on 
genotoxic drugs is to rely on the reinforcement of the G2-
prophase checkpoint or, more precisely, on the prevention of 
adaptation to this specifi c checkpoint, which shifts DSB repair 
from error-free to error prone because of innate cell-cycle 
properties.
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